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Abstract
Prostate cancer (PCa) is the fifth most common cause of cancer-related deaths in men 
globally. Androgen receptor (AR) signalling plays a vital role in initiation and progres-
sion and antiandrogens are standard of care first-line therapeutics. However, resistance 
frequently develops resulting in metastatic castration-resistant prostate cancer (mCRPC). 
Management of CRPC is currently chemotherapy and/or radiotherapy but is mostly 
palliative due to rapid development of resistance. The need for novel approaches to 
eliminate mCRPC is compelling; a promising option is replication-selective (oncolytic) 
adenoviruses with demonstrated efficacy in preclinical models of multidrug-resistant 
PCa. The safety of various viral mutants has been confirmed in numerous clinical trials 
with minimal toxicity in patients. Importantly, oncolytic adenoviruses synergise with the 
current standard of care for mCRPC even in treatment-resistant cells. In early phase I–II 
clinical trials, promising efficacy in patients with localised PCa was reported after intra-
tumoural administration, and phase III trials are underway. To enable systemic delivery, 
for targeting of mCRPC, further developments are necessary because of the short half-life 
of the adenoviral mutants in human blood. Current progress in preventing the high-
affinity binding of adenovirus to erythrocytes, hepatocyte uptake, and elimination by 
hepatic Kupffer cells will be described.
Keywords: prostate cancer, oncolytic adenoviruses, androgen, treatment resistance, 
viral modifications
1. Introduction
The current treatment approaches for prostate cancer (PCa) are successfully managing local 
disease with a reported 5-year survival rate of 100% [1]. At this stage, the treatment options 
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are surgery (radical prostatectomy), radiation therapy, and androgen deprivation therapy 
(ADT), which includes castration, androgen receptor (AR) inhibition, and combined thera-
pies. Castration is classified as either surgical (orchiectomy) or medical, for example, admin-
istration of luteinizing hormone-releasing hormone (LHRH) agonists or antagonists. Current 
use of AR inhibitors includes the nonsteroidal antiandrogens (NSAA) nilutamide, flutamide, 
and bicalutamide, which have demonstrated better tolerability than earlier steroidal antian-
drogens such as cyproterone acetate. Combined androgen blockade (CAB) refers to the use 
of castration and AR antagonists combined [2]. In contrast, late-stage hormone-independent 
metastatic PCa has a 5-year survival rate of only 29% because of the development of resistance 
to all current therapeutics including cytotoxic drugs [1]. There is an unmet medical need for 
management of late-stage PCa. Efforts to improve the survival of patients with metastatic 
PCa have led to the development of novel therapeutics with the majority of agents target-
ing the androgen pathway, for example, the NSAA ARN-509 (Aragon Pharmaceuticals) and 
the androgen synthesis inhibitor abiraterone [3, 4]. However, only limited survival benefits 
and development of resistance have been observed with the new agents. A promising novel 
class of therapeutics that act through entirely different mechanisms than traditional cytotoxic 
and targeted drugs is oncolytic viruses. Currently, no oncolytic virus has been approved for 
treatment of PCa, although numerous phase I–II trials have been completed with promising 
outcomes and phase III trials are underway [5]. The most promising preclinical and clinical 
efficacy has been reported for various PCa-selective replicating adenoviral mutants that lyse 
cancer cells and leave normal cells unharmed and, in addition, resensitise drug-resistant can-
cer cells to chemotherapeutics [6–8].
1.1. Oncolytic viruses and prostate cancer
Gene therapy with oncolytic viruses is currently one of the most promising approaches for 
cancer elimination based on both preclinical data and results from numerous clinical trials. 
While classical gene therapy uses nonreplicating viruses as vectors to deliver transgenes to 
cancer cells, oncolytic virus therapy employs the lytic properties of replicating viruses to lyse 
cancer cells in addition to expression of cytotoxic transgenes to enhance efficacy and spread 
within the tumours [9]. Oncolytic viruses are engineered to replicate selectively in tumour 
cells and are most often genetically modified to selectively infect, propagate, and kill cancer 
cells without affecting normal cells [9, 10].
The concept of using replicating viruses in cancer treatment is not new; over a century ago, 
it was noted that tumours regressed in patients after naturally occurring systemic viral infec-
tions [10, 11]. During 1950–1980, several clinical trials were carried out to assess the ability 
of wild-type viruses to eliminate cancer, including the yellow fever, hepatitis, adenoviruses, 
and West Nile fever viruses [12]. However, the outcomes were not conclusive due to failure of 
infection control and spread to both healthy and malignant cells with poor patient outcomes. 
At present, it is well known that most cancer cells have impaired innate immune responses 
with decreased protection for viral infection, for example, altered interferon activity, resulting 
in enhanced viral replication in cancer cells compared to normal cells [13]. For this reason, the 
main challenges with viral therapies today are to prevent replication in normal cells rather 
than increase replication in tumour cells (Figure 1).
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In order to generate viruses that are cancer-selective, the functions of the viral gene-prod-
ucts must be fully understood to enable selection of the appropriate genes for engineer-
ing. One of the first oncolytic viral mutants for targeting of cancer cells was generated in 
1991, by Martuza et al. [14]. The virus, a herpes simplex virus type 1 (HSVI) deleted in 
the thymidine kinase (TK) gene, which is essential for replication in normal cells, dem-
onstrated good results in killing human glioblastoma cells both in vitro and in models in 
vivo [14]. A modified adenovirus, Oncorine or H101 (based on Onyx-015; [15]), was the 
first genetically engineered oncolytic virus to be approved for cancer therapy [16]. In 2005, 
the Chinese FDA granted market approval for Oncorine as an anticancer agent for hepatic 
and head and neck cancers. The phase III clinical trial that led to the approval assessed the 
benefits of adding Oncorine to cisplatin-based chemotherapy in the treatment of advanced 
head and neck squamous cell tumours by intratumoural administration. The objective 
response rates for the combination treated group were reported at 79%, while cisplatin 
alone resulted in 40% regression of injected tumours. However, no overall survival benefits 
were observed. The only other oncolytic virus on the market is Imlygic or T-VEC (Amgen), 
an HSVI mutant expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) 
[17]. Imlygic was licenced in 2015 for melanoma by the FDA and approved in Europe in 
2016 and in Australia in 2015. Currently, there are several engineered oncolytic viruses 
undergoing phase III clinical trials including a poxvirus (Pexa-Vec; JX-594; Transgene) for 
advanced hepatocellular carcinoma and the adenovirus mutant (CG0070; Cold Genesys) 
for bladder cancer [10]. During 2001–2014, six clinical trials investigating oncolytic virus 
therapy for recurrent localised prostate cancer were reported; four of them evaluated ade-
novirus-based therapies and two reovirus-based therapies, summarised in Table 1 [18–23]. 
Figure 1. Selective replication and killing of cancer cells. Oncolytic viruses are engineered to replicate only in cancer cells 
by deleting viral genes that are essential for viral propagation in normal cells and are complemented in cancer cells by the 
altered gene expression in tumours. Alternatively, tumour-specific promoters are inserted in the viral genome to drive 
viral gene expression and propagation in cancer cells only. While oncolytic viruses may infect normal healthy cells viral 
propagation cannot proceed. In contrast, in cancer cells, viral infection leads to potent viral gene expression, genome 
amplification and virion assembly followed by virus-induced cell lysis and spread to surrounding tumour tissue.
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Currently, several phase I–II trials are ongoing using modified oncolytic adenoviruses. 
Although the development and use of oncolytic viruses have resulted in promising pre-
clinical and clinical results, several challenges remain such as premature elimination of 
virus by the host immune system, viral pathogenic mechanisms, and failure to target all 
lesions at metastatic sites.
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Phase I Ongoing Ongoing [60]
Reolysin® None (wild type) Phase I
5
Grade 1 and 2
Intravenous
51% decrease in PSA level 
in one patient with prostate 
cancer [22]
Reolysin® None (wild type) Phase I
4
Low, dose-limiting 
grade 4 neutropenia 
in one patient
Intravenous
30% decrease in PSA level 
[23]
Table 1. Published prostate cancer clinical trials with oncolytic viruses.
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2. Development of oncolytic adenoviruses
The most promising oncolytic viruses are genetically modified adenoviruses. Adenoviral 
mutants are continuously being developed to further improve on selectivity and efficacy. 
Adenovirus was discovered in the 1950s when it was isolated from adenoid tissues [24]. 
The linear double-stranded DNA genome, 30–38 kb, is enclosed in a protein capsid, forming 
70–100 nm virion particles with icosahedral symmetry. There are more than 50 subtypes of the 
human adenovirus family that infect a broad range of host tissues often causing acute mild 
disease including respiratory infections, epidemic conjunctivitis, and infantile gastroenteritis 
[25, 26]. Despite the ability of certain subtypes to induce cancer in rodent models and trans-
form cultured cells, there is no evidence to date that adenoviruses cause cancer in humans [27]. 
Currently, most clinical and preclinical studies have employed adenoviral mutants generated 
from type 5 (Ad5) because of its proven safety record and known functions.
2.1. Structure of adenoviruses
The viral capsid consists of 240 hexon and 12 penton proteins with fibre proteins projecting 
from the pentons and several small proteins that aid in stabilising the icosahedral structure 
[28]. The DNA containing core harbours additional proteins, the major polypeptide V and VII, 
a minor arginine-rich protein μ, which is covalently attached to the 5′-ends of the DNA, and 
the terminal proteins that bind to the DNA ends to act as primers for DNA replication. The 
viral DNA is wrapped around polypeptide VII similar to human DNA and histone proteins, 
and polypeptide V binds to the pentons to serve as a bridge between the core and the capsid.
The first adenoviral genome to be sequenced was from subtype 2 (Ad2), composed of 35,937 
base pairs (bp) [29]. Since then, the majority of subtypes have been sequenced and found to 
have similar genome organisation and functional gene products as Ad2, including Ad5. The 
genome is divided into early expressed units (E1A, E1B, E2A, E2B, E3, and E4), delayed early 
units (IX and IVa2), and late units (L1–L5). The early units are the first to be expressed and 
encode proteins responsible for initiating transcription of other viral genes and for chang-
ing the intracellular environment to support viral production [30, 31]. The E1A proteins are 
required for productive infection and induce S-phase, cellular DNA synthesis and activate 
viral gene expression. The E2 proteins code for the viral DNA polymerase, which is essential 
for viral genome amplification. The E3 and E4 proteins are not essential for viral replication 
but prevent premature cell death of infected cells in response to the host immune defence 
and inhibit the DNA-damage repair, respectively. The late regions encode the viral structural 
proteins after viral genome amplification to encapsulate newly synthesised viral DNA. The 
VA RNA I and II reduce stimulation of the interferon response, delay cellular microRNA 
processing, and control the expression of host genes. Both ends of the genome contain the 
100 bp inverted terminal repeats (ITRs), which serve as the origin of replication, and the viral 
packaging sequence (~200 bp), which is located next to the left ITR.
The viral particle enters the host cell through receptor-mediated endocytosis due to the 
interactions between the viral fibre and coxsackievirus and adenovirus receptor (CAR), and 
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between pentons and integrins, mainly αvβ3 and αvβ5. The viral DNA is released in the 
endosome and transported to the nucleus where E1A is expressed constitutively, initiating 
expression of other early genes and hijacking the host cell DNA-synthesis machinery [31]. 
After complete viral genome amplification and assembly of new particles, the host cell is 
lysed and viruses spread and infect surrounding cells [32].
2.2. Anticancer activity of adenoviruses
Clinical evaluation of adenoviruses as oncolytic therapeutics started shortly after the discov-
ery in the 1950s [11, 33]. The small genome is easy to engineer with known functions of the 
majority of the gene products, the genome is not integrated into the host cell DNA, the clinical 
safety profile is excellent with only flu-like side effects, and the natural tropism to epithelial 
cells renders adenocarcinomas, including PCa, excellent targets. Clinical developments have 
been limited to some extent because of the frequent downregulation of the native adenovirus 
receptor CAR in many tumours and the presence of preexisting antiadenoviral antibodies. 
A majority of the population has been infected with adenovirus at some point [27]. Several 
approaches have been explored to solve these limitations and are described below.
2.2.1. Viral fibre modifications
A promising and now common strategy that has been assessed in both preclinical and clinical 
studies is the modification of various regions of the viral capsid to enhance the affinity and 
therapeutic effects in CAR-negative cancer cell lines [27]. Several teams have evaluated fibre 
modifications that incorporate a partial peptide sequence from fibronectin, containing an argi-
nine-glycine-aspartate-4C (RGD-4C) motif into the HI-loop of the fibre-knob, which enhances 
binding to αvβ3- and αvβ5-integrins and enables CAR-independent uptake [34]. RGD-modified 
viruses have improved oncolytic actions compared to unmodified virus in CAR-negative can-
cer cells. This strategy has proven to be efficacious for targeting of several solid cancers [35].
2.2.2. Chimeric viruses
The strategy of generating chimeric mutants has the advantage of employing multiple bind-
ing motifs from various parental viruses resulting in a broader transduction range of host 
cells [36]. For example, ovarian cancer cells were more efficiently targeted by adenovirus type 
3 (Ad3) that binds to receptors including CD46 and CD80/CD86, but not CAR, and the Ad3 
fibre was subsequently inserted in Ad5 to replace the native Ad5 fibre [36, 37]. The resulting 
chimeric Ad5/3 was more efficient in targeting ovarian cancer cells than Ad5 [38].
2.2.3. Antibody fusion constructs
A novel approach to improve adenovirus selectivity is the use of antibody fusion constructs, 
where two antibodies are used; one targets adenovirus capsid proteins, for example, using 
an antifibre knob antibody, and the other targets specific membrane receptors on the tumour 
cells [32, 33]. One promising cellular target antigen is the folate receptor, which is overex-
pressed in breast, ovarian, lung, and brain cancer cells [39]. This strategy resulted in improved 
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selectivity and higher affinity of adenovirus to the tumour cells. A disadvantage of this tech-
nique is that the antibody binding to virus is lost in the progeny virions.
2.2.4. Complementation deletions
The most common strategy to generate replication-selective oncolytic adenoviral mutants is 
by introducing mutations in viral genes that are vital for replication in normal cells but are 
complemented by the altered cell cycle regulation in tumour cells (Figure 1). The first oncolytic 
adenovirus that was generated (dl1520, Onyx-015) was constructed by deleting the viral E1B55K 
protein, which binds to cellular p53 [15]. Inactivation of p53 is vital for adenovirus replication in 
normal cells to prevent apoptosis as a defence response to viral infection. In most cancers, p53 
is nonfunctional through either direct mutations or mutations of p53-regulatory proteins [40]. 
It was demonstrated that adenoviral mutants that do not express E1B55K replicate exclusively 
in cancer cells lacking functional p53. Several versions of E1B55K-deleted mutants have shown 
promising oncolytic activity in spite of attenuated viral replication in numerous solid cancers. 
It is now known that E1B55K is crucial for the export of viral mRNA from the nucleus, giving a 
rational explanation for the limited replication of the virus in cancer cells [41]. Ongoing work is 
aimed at designing mutants with nonattenuating deletions to improve replication and efficacy 
in cancer cells. An example is the E1ACR2-deleted mutants that replicate selectively in cells with 
deregulated pRb-p16 pathway [42, 43]. The deletion of the small pRb-binding CR2-region in 
the E1A gene prevents binding to pRb, and thus these mutants cannot replicate in normal cells. 
Several versions of oncolytic adenovirus based on the deletion of E1ACR2 (e.g., Ad5/3Δ24hCG) 
have been designed and are under clinical evaluation for different types of cancers [43].
3. Prostate cancer–specific oncolytic adenoviruses
Oncolytic adenoviruses provide a promising treatment option for PCa due to their unique mode 
of action that synergises with current treatment modalities. There are two successful approaches 
that have been explored when targeting PCa. The first approach was to drive viral replication by 
prostate-specific promoters replacing the native viral promoter; this strategy is feasible because 
of the frequent overexpression of AR-regulated genes such as the prostate-specific antigen (PSA) 
and prostate-specific membrane antigen (PSMA) [44, 45]. Numerous viruses have been devel-
oped utilising various combinations of androgen-response elements (ARE) present in these 
genes [46]. The second strategy is the complementation deletions (see Section 2.2.4).
3.1. Prostate-specific antigen (PSA) regulatory elements
Several specific PSA regulatory elements have been explored to control adenovirus replication, 
including AREs and the PSA enhancer, which are located upstream of the promoter. The mutant 
CG7060 was constructed to express E1A from the PSA promoter/enhancer and showed selec-
tive replication and cell killing in prostate cancer cells [44]. In animal models using the PCa cell 
line LNCaP (AR-positive, PSA-expressing), tumour xenografts were grown in mice and were 
injected intratumourally with CG7060. During the first 2 weeks, the tumour volume increased 
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slightly followed by a rapid decrease in growth. By 6 weeks, 50% of the mice were tumour-
free [44]. In a clinical trial including 20 patients with locally recurrent PCa, CG7060 showed 
an acceptable safety profile and was not associated with significant toxicity (<grade 3) [18]. In 
addition, promising anticancer activity was suggested based on the reduction in PSA levels. A 
more recent and improved version of the CG7060 virus is CG7870, which has the PSA enhancer/
promoter controlling E1B expression, while E1A expression is regulated by the rat probasin 
promoter (AR-regulated) [47]. CG7870 replicates 104–105 times more efficiently in PSA-positive 
cells than in PSA-negative cells, which is translated into 10,000 times higher cell killing activity 
[7, 48]. CG7870 was assessed in phase I and II trials for the management of locally recurrent pros-
tate cancer through intratumoural administration and in hormone refractory metastatic pros-
tate cancer through intravenous administration [19, 49]. In both settings, CG7870 was reported 
to significantly reduce PSA levels. Moreover, CG7870 synergised with other DNA-damaging 
therapies including radiotherapy or taxane chemotherapy in preclinical models [5, 7, 48].
3.2. Prostate-specific membrane antigen (PSMA) regulatory elements
PSMA is expressed in the prostate epithelial cell membrane and is significantly elevated in 
PCa cells compared to normal prostate cells and parallels the increases in Gleason score [50]. 
There are two identified transcriptional regulatory elements: the PSMA enhancer core (PSME) 
in the third intron of the PSMA gene (FOLH1) and the 1.2 kb upstream promoter of FOLH1 
[51]. PSME is the key element for the prostate-specific expression of PSMA and is negatively 
regulated by androgens, which explains the high level of PSMA in prostate cancer after cas-
tration, unlike the PSA enhancers/promoters, which depend on androgen for activity [52]. 
The feasibility of using PSME as a regulatory element to control viral replication in PCa tissue 
has been evaluated by constructing the mutant Ad5-PSME-E1A with replication regulated 
by PSME-driven expression of E1A [52]. Castrated mice with prostate tumour xenografts 
received an intratumoural injection of Ad5-PSME-E1A or control virus, resulting in signifi-
cant tumour regression only in Ad5-PSME-E1A-treated animals [52]. These outcomes suggest 
that PSME-mediated oncolytic adenovirus may be a promising strategy for management of 
PCa patients after hormonal therapy failure.
3.3. Prostate-specific chimeric regulatory elements
To further improve on the selectivity of viral mutants, chimeric prostate-specific enhancer-
promoter elements were generated and explored [44, 53]. The combination of regulatory ele-
ments from PSA and PSMA was named prostate-specific enhancing sequence (PSES) and 
was inserted in Ad5 to generate Ad-UI1 and Ad-UI2 with the E1A and E4 genes controlled by 
the PSES [53]. Ad-UI1 is armed with the prodrug-converting enzyme thymidine kinase (TK) 
from HSV. Ad-UI1 showed selective cytotoxicity against androgen-independent PSA/PSMA-
expressing prostate cancer cells in preclinical models of PCa [53].
In another approach, a triplet of prostate-specific enhancers was constructed to regulate adeno-
virus replication generating Ad[I/PPT-E1A] with E1A under the control of a complex chimeric 
promoter/enhancer sequence designated PPT [54, 55]. PPT is comprised of the T-cell recep-
tor γ-alternate reading frame protein promoter (TARP) and the PSMA and PSA enhancers. 
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The chimeric sequence is shielded from interfering adenoviral promoter-sequences by the 
mouse H19 insulator. Ad[I/PPT-E1A] demonstrated high and prostate-specific replication both 
in the presence and absence of androgens with promising oncolytic effects in PCa cell lines. 
Moreover, LNCaP xenograft tumours in mice regressed after intratumoural administration of 
Ad[I/PPT-E1A].
3.4. Targeted replication of adenovirus through complementation deletions
Several modified versions of Onyx-015 have been designed to develop prostate-specific onco-
lytic adenoviruses [15, 56]. For example, Ad5-CD/TKrep is armed with the cytosine deaminase 
(CD) and TK suicide genes [57]. In a phase I study, the intratumoural administration of Ad5-CD/
TKrep was evaluated in locally recurrent prostate cancer in combination with the prodrugs 
5-fluorocytosine (5-FC) and ganciclovir [20]. Ad5-CD/TKrep reduced PSA levels with a good 
safety profile; 44% of patients showed more than 25% decreases in PSA and 19% showed more 
than 50% decreases in PSA. Tumour cell killing at the administration sites was demonstrated by 
biopsies 2 weeks later. Interestingly, two patients were cancer free at 1 year follow-up.
Later, a second-generation of Ad5-CD/TKrep was developed; Ad5-yCD/mutTKSR39rep-ADP 
expressing the adenovirus death protein (ADP) and an improved yeast CD/TK chimeric suicide 
construct [58]. Ad5-yCD/mutTKSR39rep-ADP showed higher cancer cell killing activity in pre-
clinical studies compared to the parental virus. Moreover, in a phase II trial, promising synergis-
tic anticancer activity was seen in combination with radiation therapy [21]. Another version of 
this mutant is (Ad5-yCD/mutTKSR39rep-hNIS), which in addition to the chimeric suicide gene 
expresses the human sodium iodide symporter (hNIS), which serves as a reporter gene to enable 
localisation through noninvasive single-photon emission computed tomography (SPECT/CT) 
[59]. The most recent version of these mutants is Ad5-yCD/mutTKSR39rep-hIL12, which instead 
of hNIS expresses the human interleukin 12 (IL-12) [60]. IL-12 is a proinflammatory cytokine 
released by antigen-presenting cells to activate the innate and adaptive immune responses. IL-12 
has reported antitumour activity by overcoming the immune suppressive nature of the tumour 
microenvironment and inhibiting angiogenesis. Local administration of Ad5-yCD/mutTKSR-
39rep-hIL12 may evade systemic toxicity of IL-12 while maintaining its therapeutic activity locally. 
Systemic administration of Ad5/3Δ24hCG, targeting the Ad3 receptor expresses the β-chain of 
human chorionic gonadotropin (hCGβ), was reported to have anticancer activity in mice with 
castration-resistant lung metastasis of PCa, resulting in significant survival advantages [43].
4. Challenges using oncolytic adenoviruses for prostate cancer
The promising results from clinical trials with oncolytic adenoviral mutants are, in the majority 
of cases, derived from localised PCa and intratumoural administration [18, 20, 21]. However, 
the poor survival outcomes for late-stage PCa patients are due to metastatic lesions in skel-
eton and lymph nodes. While the oncolytic mutants readily spread within the tumour tissue 
after local administration, metastatic lesions need to be targeted through systemic delivery, 
which is currently not feasible due to the high-affinity binding to erythrocytes, other factors 
present in the blood, and through elimination of virus from the circulation by the liver [8, 61].




A major hurdle in achieving efficient tumour uptake after systemic delivery of oncolytic ade-
noviruses is the preexisting immunity to virus since the majority of the population has previ-
ously been infected with adenovirus. One strategy to overcome preexisitng immunity is to 
encapsulate the virus in liposomes. It was demonstrated that despite the presence of adenovi-
rus antibodies, liposome-coated virus infected tumour cells in preclinical in vivo models [62]. 
Another strategy, which has also been explored in noncancer research, is the administration of 
anti-CD20 antibodies to inhibit T cells and deplete B cells from the host. This strategy resulted 
in enhanced replication of adenoviruses regardless of preexisting adenoviral immunity [63]. 
A more sophisticated approach is the “Trojan Horse”, in which the virus is delivered within a 
host cell that targets tumours. A similar approach is incorporation of the E1A gene into cyto-
toxic T lymphocytes (CTL) with expression controlled by the cell activation-dependent CD40 
ligand promoter [64]. After transduction of CTLs with E1-deficient adenoviral vectors and 
activation by CD40, E1A was expressed and infectious virus was produced. Viral replication 
was tightly associated with CTL activation by its specific tumour-associated antigen, resulting 
in targeted delivery of oncolytic virus to the tumour [64].
4.2. Binding to erythrocytes
Human erythrocytes express CAR and complement receptor-1 (CR1) that bind to adenovirus 
with high affinity [65]. The binding significantly decreases the levels of free circulating virus, in 
turn attenuating viral infection of tumour target tissue. Therefore, erythrocyte binding is a great 
challenge for systemic administration of oncolytic adenoviruses. To overcome these obstacles, it 
might be possible to shield the virus with a layer of hydrophilic polyethylene glycol, modifica-
tions of the capsid proteins, or as described above with liposome encapsulation [62, 66].
4.3. Uptake by nontargeted healthy tissue
Most adenoviruses are eliminated from the circulation by Kupffer cells through nonreceptor-
mediated uptake [67, 68]. For Ad5, up to 90% is taken up by hepatocytes and Kupffer cells in 
the liver within minutes of intravenous delivery in humans, drastically preventing sufficient 
amount of virus to reach the targeted tumours [68]. To increase the amount of circulating 
virus, several strategies have been investigated. One preclinical study explored preadmin-
istration of warfarin, which depleted Kupffer cells and prevented hepatocyte binding and 
consequently improved the anticancer activity of an intravenously administered oncolytic 
adenovirus [69]. Although warfarin administration may not be feasible in patients, the study 
demonstrated that circulating levels of Ad5 mutants could be increased by blocking liver 
uptake. The major key factors associated with liver sequestration of oncolytic Ad5 mutants 
are the blood coagulation factors IX (FIX) and X (FX) that bind to the capsid proteins and 
mediate erythrocyte and hepatocyte binding [70]. To avoid these interactions, various chi-
meric capsid mutants have been generated with altered hexon and/or fibre proteins includ-
ing the Ad3/Ad11 mutant ColoAd1 (enadenotucirev; PsiOxus) that is currently in phase I–II 
trials with reported promising outcomes in several solid cancers after systemic delivery [71]. 
Another mutant Ad5/48 with hexon proteins from Ad48, which have low affinity to FX, dem-
onstrated decreased liver uptake in preclinical models [72].
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4.4. Endogenous cytokines
Systemic virus administration stimulates the release of a range of cytokines such as interfer-
ons (IFN types 1, 2, and 3) [73]. Their major roles are to induce apoptosis of virus-infected cells 
and promote resistance to infection in noninfected cells. Moreover, IFNs stimulate the adap-
tive immune system, mainly the dendritic cells, to initiate long-term immunity. One strategy 
to overcome the IFN-response is to pretreat the patients with histone deacetylase inhibitors 
(HDACi) that induce epigenetic changes preventing antiviral cytokine activity at the tumour 
sites and significantly enhancing systemic efficacy of oncolytic mutants [74]. Delivery of the 
virus within mesenchymal stem cells derived from the patient may also aid in avoiding the 
IFN responses since mesenchymal stem cells suppress activated T cells [75].
5. Future directions
The efficacy of numerous oncolytic viruses in cancer management has been established, 
although only two mutants have been granted market approval to date [15, 17]. Major clini-
cal drawbacks associated with oncolytic adenoviruses are the significant losses of virus after 
systemic administration resulting in low doses reaching the tumour lesions. In addition, the 
complexity of designing potent and selective oncolytic viruses without toxicity to normal cells 
but potent cancer killing activity requires further optimisations. Ongoing work is focused on all 
aspects of delivering optimised mutants to metastatic lesions. One novel approach is to employ 
less common serotypes, including Ad3, Ad11, and Ad48, that are more resistant to elimination 
after intravenous administration. Natural infection with these serotypes is less frequent and 
preexisting immunity is rare. In addition, the utilisation of other uptake receptors than those of 
Ad5, CAR, and αvβ3- and αvβ5-integrins is an advantage both for improved cancer-cell uptake 
and decreased erythrocyte and blood-factor binding. A similar approach is the use of chimeric 
adenoviral mutants including replication-selective alterations of, for example, the Ad5 genome 
and exchange of capsid proteins from other serotypes such as Ad3 and Ad11. A method for 
generating cancer cell–selective optimised novel chimeric mutants is “directed evolution” 
[75]. This concept involves pooling of several serotypes of adenovirus followed by numerous 
passaging of virus on the cancer cell type of interest, which promotes recombination between 
serotypes. This process represents an accelerated simulation of the natural selection of viruses, 
and the most potent mutant can be selected from the resultant viral pools for further study. 
The methodology can be applied to most epithelial cancer cell lines. To date, a potent onco-
lytic adenovirus has been generated using this approach, ColoAd1 (enadenotucirev; PsiOxus), 
which entered phase I–II trials with reported promising outcomes in several solid cancers after 
systemic delivery [71]. Potency and selectivity on colon cancer cells were significantly higher 
compared to Onyx-015 [76]. ColoAd1 was selected on colon cancer cell lines and was not evalu-
ated in PCa patients; however, a similar approach using prostate cancer cell lines may lead to 
the generation of prostate-selective chimeric adenoviruses suitable for systemic administration.
A major advantage of using adenoviruses as anticancer therapeutics is the safety with only 
self-limiting flu-like side effects [77]. While administration of current oncolytic adenoviral 
mutants as single agents has not resulted in significant increases in survival, in combination 
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with cytotoxic drugs and immune factors, efficacy was greatly improved [7, 48]. One strategy 
to overcome the high level of resistance to anticancer immune responses is to include trans-
genes into the viral genome, such as GM-CSF and IL-12, to further improve the anticancer 
activity by boosting antitumour immunity [8, 78]. Arming oncolytic viruses with immune 
stimulatory factors show promise since intralesional administration of virus might induce a 
synergistic action between viral oncolysis and antitumour immune responses. This concept is 
particularly significant for prostate cancer management, as prostate cancer usually does not 
respond to management with immunotherapeutic agents such as check point inhibitors, due 
to the immunosuppressive character of this cancer [79]. In addition, the immune responses 
resulting from cancer cell lysis and death are anticipated to target metastatic tumours even 
after clearance of the oncolytic virus from the body.
Other issues are the variable susceptibility of tumours to oncolytic adenoviral mutants, likely 
caused by the specific gene alterations in each tumour type [80]. It may be possible to char-
acterise each patient tumour and select from a panel of oncolytic adenoviruses specifically 
targeting the identified mutations. A more practical approach to enhance oncolytic efficacy 
is through combining the mutants with other treatment modalities including cytotoxic drugs 
and small molecule–targeted therapies [80, 81]. A recent example is the combination of the 
H101 mutant with a small interfering RNA targeting Bcl2 (siBcl2) [80]. In preclinical studies, 
the combination resulted in significantly increased tumour cell cytotoxicity and apoptosis 
compared to either agent alone. In vivo tumour xenograft studies demonstrated that combin-
ing H101 with siBcl2 significantly reduced tumour growth and prolonged survival.
6. Conclusions
For patients with early-stage prostate cancer, the current treatment modalities are efficient, 
with 5-year progression-free survival rates of more than 90%. On the other hand, for patients 
with advanced PCa (stages III and IV), there is currently no effective therapy. Although the 
latest therapeutic developments for late-stage metastatic PCa have provided a variety of man-
agement options that offer significant clinical benefits for patients, the disease still has almost 
100% mortality rate at this stage. The median survival after development of hormone resis-
tance is 14 months. Current treatment options have modest effects on survival, extending life 
by around 2.5–5 months, and are associated with increased treatment costs [82]. Therefore, 
the need for novel therapies is pressing. Oncolytic viruses have proven potential for the future 
management of PCa. Several factors make adenoviruses valuable anticancer agents, such as 
the biology of the viruses is well understood, the viral genome is small and easy to manip-
ulate, and the viruses can induce direct cell death, synergise with apoptosis-inducing che-
motherapeutic drugs and stimulate the immune system to develop cancer-specific immune 
responses. The anticancer mechanisms of adenoviruses are unique without the development 
of cross-resistance to current therapeutics and have only mild side effects.
Adenoviruses are the most attractive and promising oncolytic virus species that have yet 
been developed for treatment of different types of solid cancers including PCa. Reports from 
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phase I–II clinical trials, including PCa patients, demonstrate that these viruses have excellent 
safety profiles that have been reproduced in thousands of patients. The reported efficacy is 
promising because of the synergistic interactions between oncolytic adenoviruses and chemo-
therapy/radiotherapy. Phase III clinical trials are ongoing to assess the efficacy of oncolytic 
mutants in locally recurrent and high-risk local prostate cancers [21]. If the results of these 
trials confirm the efficacy and safety, the first oncolytic virus therapy for PCa patients may 
become a reality in the future. Additionally, arming the viruses with cytotoxic transgenes 
and immune stimulatory factors represents a promising approach to enhance efficacy in both 
localised and metastatic PCa. A recent advancement in the development of optimised onco-
lytic viruses is the generation of chimeric viruses by utilising serotypes that are more resistant 
in the circulation. An effective but labour-intense approach is to generate chimeric oncolytic 
adenovirus with enhanced potency, circulating half-life and selectivity to specific cancer types 
by directed evolution [76]. The major drawback of oncolytic adenoviruses is the disappoint-
ing anticancer activity against distant metastatic tumours after systemic administration, and 
by employing novel chimeric serotypes, it may be possible to develop superior mutants with 
properties suitable for intravenous delivery. The adenoviral mutants Ad5/3Δ24hCG demon-
strated promising anticancer activity in preclinical metastatic hormone-resistant PCa models, 
which prolonged survival in vivo [43]. If the same results are reproduced in patients, a great 
impact on the management of metastatic PCa can be anticipated. We predict that in the near 
future oncolytic adenoviruses will be a treatment choice for this indication and will add to the 
novel therapies that aim to cure late-stage castration-resistant prostate cancer.
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